This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Perrigo (PRGO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Procter & Gamble Rewards Investors Amid Coronavirus Despair
by Zacks Equity Research
Although U.S. companies are reeling under the uncertain impacts of the coronavirus, Procter & Gamble's (PG) recent move to hike dividend comes as a sigh of relief for investors.
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Sanofi to Withdraw Zantac After FDA Warns of Carcinogens
by Zacks Equity Research
The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.
Why Is Perrigo (PRGO) Down 11% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.
Perrigo (PRGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -2.75% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
InMode (INMD) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.
QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe
by Zacks Equity Research
QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.
PRGO or PAHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PRGO vs. PAHC: Which Stock Is the Better Value Option?
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
Align (ALGN) Rides on Volume Expansion Despite Cost Concerns
by Zacks Equity Research
We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.
Will Perrigo (PRGO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
by Zacks Equity Research
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.